Inscriere cercetatori

Premii Ad Astra

premii Ad Astra

Asociația Ad Astra a anunțat câștigătorii Premiilor Ad Astra 2022: http://premii.ad-astra.ro/. Proiectul și-a propus identificarea și popularizarea modelelor de succes, a rezultatelor excepționale ale cercetătorilor români din țară și din afara ei.

Asociatia Ad Astra a cercetatorilor romani lanseaza BAZA DE DATE A CERCETATORILOR ROMANI DIN DIASPORA. Scopul acestei baze de date este aceea de a stimula colaborarea dintre cercetatorii romani de peste hotare dar si cu cercetatorii din Romania. Cercetatorii care doresc sa fie nominalizati in aceasta baza de date sunt rugati sa trimita un email la cristian.presura@gmail.com

Cytogenetics, immunophenotype and biomolecular parameters-particularities in acute lymphoblastic leukemia

Domenii publicaţii > Ştiinţe medicale + Tipuri publicaţii > Articol în revistã ştiinţificã

Autori: M. Puiu, S. Arghirescu, M. Bataneant, R. Firescu, L. Stana, M. Baica, M. Mihailov, M. Serban

Editorial: Nature Publishing Group, European Journal of Human Genetics, vol. 15, supplement 1, p.163, 2007.

Rezumat:

Background. Acute lymphoblastic leukemia (ALL) refers to a group of heterogeneous diseases with different clinical expression and prognosis. Therefore, patients require precise and complete initial evaluation of risk factors including cytogenetics, immunophenotype and biomolecular assessment in order to plan an individualised, optimal treatment regimen.
Objectives. We aimed at evaluating the biological profile of leukemic cells and its particularities in ALL.
Patients and methods. We analyzed cytogenetics, cell surface markers and biomolecular parameters in connection with clinical parameters (sex, age, risk factors, ethnic group, central nervous system leukemia, mediastinal mass) in 156 ALL patients aged 0-18 years, treated in our Clinic between 1990-2002.
Results. Compared to data from literature, in our study group we noticed no differences between sex distribution (56% vs. 57% being males), a lower proportion of patients belonging to 2-6 years age group (53.8% vs. 77%) and a double proportion of patients older than 6 years (41.6% vs. 20%). Frequency of medium and high risk forms was higher in study group (75.6% and 10.2% vs. 59.46% and 10.65%) and also the incidence of L3-ALL (3.3%). Biomolecular assessment revealed a comparable proportion of patients with t(9,22)-BCR-ABL mutation (1.28%) and a higher proportion of t(14,11) MLL-AF4 (2.56%). Leukemic cells expressed lymphoid CD10 marker in 35.07% vs. 63.01%. There were no differences between central nervous system involvement in newly diagnosed ALL (3.8% vs. 4%). These data can explain the worse prognosis of our patients.
Conclusions. Our results provide practical information that should be taken into account for planning individualized treatment.

Cuvinte cheie: leucemie, imunofenotip, citogenetica // leukemia, immunophenotype, cytogenetics

URL: http://www.eshg.org/eshg2007/downloads/ESHG2007Abstracts.pdf